Canada’s Stem Cell Network made its first direct company investment, awarding $1 million through a new Incubation Investment Award program. The initiative is intended to address a capital gap between early innovation and readiness for clinical development, manufacturing scale-up, and significant private investment. The inaugural recipient is RejuvenRx, a Montreal-based company developing a next-generation oral medicine designed to restore healthy blood-forming stem cells and rebuild the immune system. The program’s thesis leans on translational continuity from UM171, a molecule developed at Université de Montréal that boosts stem-cell transplant effectiveness in cancer patients. For the Canadian regenerative medicine ecosystem, the move is notable because it targets the specific pre-clinical-to-clinical “valley of death” where promising candidates often struggle to generate the evidence needed for downstream funding. It also signals a more hands-on approach by a longstanding sector organization toward scaling domestic health innovation.